Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens

Human Reproduction

Volumn 20, Issue 2, 2005, Pages 563-568

  van Vliet, Huib A A M ^a   Frolich, Marijke ^a   Thomassen, M Christella L G D ^b   Doggen, Carine J M ^a   Rosendaal, Frits R ^a   Rosing, Jan ^b   Helmerhorst, Frans M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

APC resistance; Oral contraceptives; SHBG; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FEMALE; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PILL; PREDICTION; RISK FACTOR; THROMBIN TIME; THROMBOSIS;

EID: 14044272824     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh612     Document Type: Article

References (22)

1. Anderson DC (1974) Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 3,69-96.
2. Barkfeldt J, Virkkunen A and Dieben T (2001) The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. Contraception 64,295-299.
3. Crona N, Silfverstolpe G and Samsioe G (1984) Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol. Contraception 29,261-270.
4. El Makhzangy MN, Wynn V and Lawrence DM (1979) Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol (Oxf) 10,39-45.
5. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV and Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133,32-37.
6. Kemmeren JM, Algra A and Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J 323,131-134.
7. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J and Grobbee DE (2004) Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood 103,927-933.
8. Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S and Chandler WL (2001) Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 63, 1-11.
9. Odlind V, Milsom I, Persson I and Victor A (2002) Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 81, 482-490.
10. Rosendaal FR, Van Hylckama Vlieg A, Tanis BC and Helmerhorst FM (2003) Estrogens, progestogens and thrombosis. J Thromb Haemost 1, 1371-1380.
11. Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K and Hemker HC (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97,233-238.
12. Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH and Tans G (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354,2036-2040.
13. Sheldon T (2002) Dutch GPs warned against new contraceptive pill. Br Med J 324,869.
14. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J and Rosendaal FR (2003) Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 122,465-470.
15. van Hylckama Vlieg A (2003) Causes of venous thrombosis: procoagulant factors and oral contraceptives [dissertation]. Leiden University, Leiden.
16. van Kammen E, Thijssen JH, Rademaker B and Schwarz F (1975) The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity. Contraception 11,53-59.
17. van Rooijen M, Silveira A, Hamsten A and Bremme K (2004) Sex hormone-binding globulin - a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol 190,332-337.
18. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp, S, Helmerhorst FM, Bouma BN and Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344,1527-1535.
19. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA and Thijssen JH (1990) Effects of seven low-dose combined oral contraceptivess on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 41,345-352.
20. van Vliet HA, Winkel TA, Noort I, Rosing J and Rosendaal FR (2004) Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost, in press.
21. Vasilakis-Scaramozza C and Jick H (2001) Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358,1427-1429.
22. World Health Organization (1996) Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. World Health Organization, Geneva.